The United Kingdom is home to one of Europe’s most vibrant life science sectors; for many scientists, clinical researchers and investors in Europe, UK partners are a natural choice for joint projects in the development of new therapy options and particularly in their commercialisation. Berlin has fostered translational science and, with both the BeCAT and BCRT, is a major international player in the development and application of Advanced Therapies, so-called “living drugs”. To further strengthen our ties in the important area of Advanced Therapies, e.g. cell and gene therapy, London’s Cell and Gene Therapy Catapult together with the Berlin’s BCRT and BeCAT are holding a meeting of the British-German Alliance for Advanced Therapies at the UK Embassy in Berlin on 26 March.
The day-long symposium comprises a series of talks led by British and German cell and gene therapy experts. They will cover key technical and clinical themes for the manufacture of advanced therapies and highlight the progress of the joint large-scale research initiative RESTORE. Attendees are also invited to join the networking dinner and to make the most out of this opportunity to meet fellow researchers and companies working in the field and hear about opportunities for international collaboration between Germany and the UK.
Spaces are limited so please make sure that you RSVP by registering here for free.
Cell and Gene Therapy Catapult: https://ct.catapult.org.uk/
About the organisers:
The Cell and Gene Therapy Catapult
The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, our mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies. We are based on the 12th floor of Guy’s Hospital in central London, with over 170 cell and gene therapy experts, state-of-the art development and viral vector laboratories. We have also built a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market in the UK and internationally.
The BIH Center for Regenerative Therapies (BCRT)
The BIH Center for Regenerative Therapies is an interdisciplinary translational research center which is jointly operated by the BIH and Charité. Its main aim is to enhance the body’s ability to use cells, factors and biomaterials as part of natural regeneration processes and to promote alternative strategies that can be used to develop innovative therapies and products. The Center's primary focus is on diseases of the immune, musculoskeletal and cardiovascular systems, as well as areas of research that straddle different medical disciplines, such as tissue homeostasis and cachexia. Between 2006 and 2018, the center was cofinanced by the Federal Ministry of Education and Research. Following a change in cofinance arrangements in 2019, the center is now being cofinanced by the Berlin Institute of Health (BIH) and known as the BIH Center for Regenerative Therapies.
Berlin Center for Advanced Therapies (BeCAT)
Established thanks to a €30 million grant from the German Council of Science and Humanities (Wissenschaftsrat), the BeCAT aims to provide the necessary infrastructure, platforms, mentality and expertise in order to facilitate the development and clinical translation of advanced therapies in the areas of regenerative medicine and haemato-oncology.